Not admitted · Not a forecast
Rules 1.1.0 · as of 14 Sep 2026
Rick Doblin · Said 26 Dec 2025 · doblin-0238
Quote
Not a forecast
“Even though FDA approval has been delayed, MAPS, dedicated therapists, advocates, and researchers, and Resilient Pharmaceuticals (formerly known as Lykos), continue to persist in efforts to make these treatments available to those who are suffering from PTSD.”
From the Desk of Rick Doblin year-end 2025 column. Doblin frames the 2024 CRL as a delay of FDA approval, not a denial, and notes Resilient continues to pursue market approval for MDMA.
Descriptive, retrospective, or a statement of preference; no future state asserted.